Document Type: Original Research

Authors

1 Department of Pathology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Radiation Oncology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Oncology, Cancer Prevention Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.30699/ijp.2020.113829.2235

Abstract

Background & Objective:  Human epidermal growth factor receptor 2 (HER-2) exhibits a vast range of expression in esophageal squamous cell carcinoma (ESCC) patients as a biomarker. This paper aimed to investigate HER-2 expression and clinicopathological parameters of esophageal SCC.
Methods:  HER-2 expression was assessed in 102 ESCC patients by immunohistochemistry. The HER-2 staining intensity , according to the Gastric HER2 Biomarker1.0.0.1 version of the college of American pathologists (CAP) protocol for gastric and gastroesophageal junction cancers, was graded as 0 (no reactivity in any of the cancer cells’ membranes); 1+ (pale or hardly noticeable reactivity in the membrane of cancer cells’ cluster [≥ 5 neoplastic cells] regardless of the positive cancer cells’ percentage); 2+ (weak-to-moderate complete, basolateral, or lateral membranous reactivity regardless of the positive cancer cells’ percentage); and 3+ ( strong complete, basolateral, or lateral reactivity in the membrane of the cancer cell cluster regardless of the positive cancer cells’ percentage).In this regard, 3+ scored samples were considered as positive. If HER-2 expression was scored 2+, an additional fluorescence in situ hybridization (FISH) was performed. Fisher's exact test was employed for investigating the correlation of HER-2 expression status with patients’ clinicopathological characteristics (including age, gender, tumor location, stage, grade, infiltration level, venous invasion, lymphatic invasion, and tumor recurrence). Kaplan-Meier analysis was done for the patients’ survival assessments.
Results:  Five patients (~5%) were HER-2 positive and no significant association was observed between HER-2 expression and clinicopathological properties. In addition, HER-2 expression status exhibited no significant association with the patients’ overall survival (P=0.9299). 
Conclusion:  HER-2 is not a suitable prognostic biomarker for Iranian ESCC patients.

Highlights

HER-2 is not a suitable prognostic biomarker for Iranian ESCC patients.

Keywords

Main Subjects

  1. Klingelhöfer D, Zhu Y, Braun M, Brüggmann D, Schöffel N, Groneberg DA. A world map of esophagus cancer research: a critical accounting. J Translat Med. 2019 Dec 1;17(1):150. [DOI:10.1186/s12967-019-1902-7] [PMID] [PMCID]
  2. Vijayan K, Eslick GD. Epidemiology and Risk Factors for Esophageal Cancer. Esophageal Cancer: Springer; 2020. p. 1-32. [DOI:10.1007/978-3-030-29832-6_1] [PMID] [PMCID]
  3. Dietz HC. TGF-β in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. J Clin Invest. 2010 Feb 1;120(2):403-6. [DOI:10.1172/JCI42014] [PMID] [PMCID]
  4. Ilson DH. Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res. 2008 Mar;2(2):85.
  5. Bird-Lieberman E, Fitzgerald RJBjoc. Early diagnosis of oesophageal cancer. 2009;101(1):1. [DOI:10.1038/sj.bjc.6605126] [PMID] [PMCID]
  6. Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W. Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary her2-negative inflammatory breast cancer. JAMA oncology. 2018 Sep 1;4(9):1207-13. [DOI:10.1001/jamaoncol.2018.1436] [PMID] [PMCID]
  7. Roskoski Jr R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Communic. 2004 Jun 18;319(1):1-1. [DOI:10.1016/j.bbrc.2004.04.150] [PMID]
  8. Márquez-Garbán DC, Gorrín-Rivas M, Chen HW, Sterling Jr C, Elashoff D, Hamilton N, Pietras RJ. Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression. Cancer Lettr. 2019 May 1;449:66-75. [DOI:10.1016/j.canlet.2019.02.009] [PMID] [PMCID]
  9. Genc AZ, Koseoglu RD, Arici A, Demir O. HER-2/neu gene analysis on endoscopic biopsy samples and gastric resection materials in gastric carcinomas. 2019. [DOI:10.15275/rusomj.2019.0410]
  10. Chung YW, Kim S, Hong JH, Lee JK, Lee NW, Lee YS, Song JY. Overexpression of HER2/HER3 and clinical feature of ovarian cancer. Journal of gynecologic oncology. 2019 May 16;30(5). [DOI:10.3802/jgo.2019.30.e75] [PMID] [PMCID]
  11. Raziee H, Taghizadeh Kermani A, Ghaffarzadegan K, Taghi Shakeri M, Ghavamnasiri MJIJoBMS. HER-2/neu Gene Overexpression in Resectable Gastric Cancer and its Relationship with Histopathologic Subtype, Grade, and Stage. 2007;10(2):139-45.
  12. Sawyers CL. Herceptin: A First Assault on Oncogenes that Launched a Revolution. Cell. 2019 Sep 19;179(1):8-12. [DOI:10.1016/j.cell.2019.08.027] [PMID]
  13. Kuznetsova M, Lopatnikova J, Shevchenko J, Silkov A, Maksyutov A, Sennikov S. Cytotoxic activity and memory T cell subset distribution of in vitro-stimulated CD8+ T cells specific for HER2/neu epitopes. Front Immunol. 2019 May 9;10:1017. [DOI:10.3389/fimmu.2019.01017] [PMID] [PMCID]
  14. Yadav K, Shimasaki N, Ow SGW, Wong ALA, Lim JSJ, Koe P, et al. Tumor pathological and immunological changes in HER2+ metastatic breast cancer (MBC) following trastuzumab combined with expanded and activated autologous natural killer (NK) cell infusion. Am Soc Clin Oncol; 2019. [DOI:10.1200/JCO.2019.37.15_suppl.e12511]
  15. Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangiu ML, Sfondrini L, Balsari A, Tagliabue E. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. Oncoimmunology. 2019 Jan 2;8(1):e1512942. [DOI:10.1080/2162402X.2018.1512942] [PMID] [PMCID]
  16. Gonzaga IM, Soares-Lima SC, de Santos PT, Blanco TC, de Reis BS, Quintella DC, de Oliveira IM, de Faria PA, Kruel CD, Andreollo NA, de Simão TA. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC cancer. 2012 Dec 1;12(1):569. [DOI:10.1186/1471-2407-12-569] [PMID] [PMCID]
  17. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC cancer. 2009 Dec 1;9(1):6. [DOI:10.1186/1471-2407-9-6] [PMID] [PMCID]
  18. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol. 2007 Sep 1;31(3):493-9. [DOI:10.3892/ijo.31.3.493]
  19. Peng JH, Zhang X, Song JL, Ran L, Luo R, Li HY, Wang YH. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma. Med. 2019 Jan;98(2). [DOI:10.1097/MD.0000000000013554] [PMID] [PMCID]
  20. Shu S, Iimori M, Nakanishi R, Jogo T, Saeki H, Oki E, Maehara Y. Changes in HER2 expression and amplification status following preoperative chemotherapy for gastric cancer. in vivo. 2018 Nov 1;32(6):1491-8. [DOI:10.21873/invivo.11405] [PMID] [PMCID]
  21. Bartley AN, Jessi Christ C, Fitzgibbons P, Hamilton SR, Kakar S, Shah MA, et al. Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens from Patients with Adenocarcinoma of the Stomach or Gastroesophageal Junction. 2017.
  22. Roskoski Jr RJPr. The ErbB/HER family of protein-tyrosine kinases and cancer. 2014;79:34-74. [DOI:10.1016/j.phrs.2013.11.002] [PMID]
  23. Cretella D. Combined use of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) as target therapy in non-small cell lung cancer (NSCLC) (Doctoral dissertation, Università di Parma. Dipartimento di Scienze Biomediche, Biotecnologiche e Traslazionali).
  24. Jørgensen JT, Nielsen KB, Kjærsgaard G, Jepsen A, Mollerup J. Gene signal distribution and HER2 amplification in gastroesophageal cancer. J Cancer. 2017;8(9):1517. [DOI:10.7150/jca.17878] [PMID] [PMCID]
  25. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, Liu B. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018 Jun 1;5(2):77-106. [DOI:10.1016/j.gendis.2018.05.001] [PMID] [PMCID]
  26. Liu Q, Borcherding NC, Shao P, Maina PK, Zhang W, Qi HH. Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance. EBioMedicine. 2020 Jan 1;51:102612. [DOI:10.1016/j.ebiom.2019.102612] [PMID] [PMCID]
  27. Shibata W, Kinoshita H, Hikiba Y, Sato T, Ishii Y, Sue S, Sugimori M, Suzuki N, Sakitani K, Ijichi H, Mori R. Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. Sci Reports. 2018 Apr 18;8(1):1-0. [DOI:10.1038/s41598-018-24375-2] [PMID] [PMCID]
  28. Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, Wang ZN, Li HQ, Zhang SB, Sun Z. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol. 2017 Dec;15(1):1-7. [DOI:10.1186/s12957-017-1132-5] [PMID] [PMCID]
  29. Luo H, Xu X, Ye M, Sheng B, Zhu X. The prognostic value of HER2 in ovarian cancer: a meta-analysis of observational studies. PloS one. 2018 Jan 30;13(1):e0191972. [DOI:10.1371/journal.pone.0191972] [PMID] [PMCID]
  30. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Molecul Biol Int. 2014;2014. [DOI:10.1155/2014/852748] [PMID] [PMCID]
  31. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, Tsurumaru M, Sasai K. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Physic. 2003 Dec 1;57(5):1323-7. [DOI:10.1016/S0360-3016(03)00782-X]
  32. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A, Fujii H. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2005 Apr;92(7):1253-60. [DOI:10.1038/sj.bjc.6602499] [PMID] [PMCID]
  33. Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol. 2012 Jun 1;29(2):933-40. [DOI:10.1007/s12032-011-9850-y] [PMID]
  34. Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M, Birner P. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010 Dec 1;34(12):1868-73. [DOI:10.1097/PAS.0b013e3181f8be17] [PMID]
  35. Maruyama T, Mimura K, Sato E, Watanabe M, Mizukami Y, Kawaguchi Y, Ando T, Kinouchi H, Fujii H, Kono K. Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br J Cancer. 2010 Aug;103(4):552-9. [DOI:10.1038/sj.bjc.6605772] [PMID] [PMCID]
  36. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, Lagarde N, Volant A. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005 Jul;93(1):107-15. [DOI:10.1038/sj.bjc.6602625] [PMID] [PMCID]
  37. Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Modern Pathol. 2007 Jan;20(1):120-9. [DOI:10.1038/modpathol.3800712] [PMID]
  38. Wu D, Xu J, Yu G, Zhang B, Wang H, Wang C, Ru G, Sun A, Shen L, Wei Q. Expression status of fatty acid synthase (FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma. Hepato-gastroenterology. 2013 Jan 1;60(121):99-106. [DOI:10.5754/hge122415]
  39. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012 Jan 15;18(2):546-54. [DOI:10.1158/1078-0432.CCR-11-2272] [PMID] [PMCID]
  40. Huang JX, Zhao K, Lin M, Wang Q, Xiao W, Lin MS, et al. HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. 2013;6(1):13-8. [DOI:10.3892/ol.2013.1348] [PMID] [PMCID]
  41. Barros-Silva JD, Leitao D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009 Feb;100(3):487-93. [DOI:10.1038/sj.bjc.6604885] [PMID] [PMCID]